Brief: Skye’S Cb1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss And Differentiated Mechanisms From Monlunabant, And Continues To Show Enhanced Combination With Tirzepatide With Durable Post-Treatment Weight Maintenance In Dio Model

Skye Bioscience

04/09/2025 12:01

Eli Lilly and Co LLY.N:

SKYE’S CB1 INHIBITOR, NIMACIMAB,  DEMONSTRATES SUPERIOR WEIGHT LOSS AND DIFFERENTIATED MECHANISMS FROM MONLUNABANT, AND CONTINUES TO SHOW ENHANCED COMBINATION WITH TIRZEPATIDE WITH DURABLE POST-TREATMENT WEIGHT MAINTENANCE IN DIO MODEL

SKYE BIOSCIENCE INC - NIMACIMAB + TIRZEPATIDE SHOWS 40% WEIGHT LOSS IN STUDIES

SKYE BIOSCIENCE INC - NIMACIMAB REDUCES REBOUND WEIGHT GAIN POST-TREATMENT

SKYE BIOSCIENCE INC - NIMACIMAB SHOWS DURABLE WEIGHT LOSS POST-TREATMENT

SKYE BIOSCIENCE INC - NIMACIMAB OUTPERFORMS MONLUNABANT IN STUDIES

Source text: ID:nGNXb4p4Kp

Further company coverage: LLY.N